Monoclonal Antibodies in the Treatment of Human B-Cell Malignancies

References

• Baumler E. Paul Ehrlich: Scientist for Life. 1984
   Google Scholar
• Pressman D., Korngold L. The in vivo localization of anti-Wagner-osteogenic sarcoma antibodies. Cancer 1953; 6: 619–623
   PubMed Web of Science ®Google Scholar
• Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495–7
   PubMed Web of Science ®Google Scholar
• Stein R., Belisle E., Hansen H. J., Goldenberg D. M. Epitope Specificity of the Anti-(B-Cell Lymphoma) Monoclonal Antibody, LL2. Cancer Immunol Immunother 1993; 37: 293–298
   PubMed Web of Science ®Google Scholar
• Nadler L. M., Stashenko P., Hardy R., Schlossman S. F. A monoclonal antibody defining a lymphoma-associ-ated antigen in man. Journal of Immunology 1980; 125: 570–7
   PubMed Web of Science ®Google Scholar
• Epstein A. L., Marder R. J., Winter J. N., Stathopoulos E., Chen F.-M., Parker J. W., Taylor C. R. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodi-agnostic and immunotherapeutic potential. Cancer Research 1987; 47: 830–840
   PubMed Web of Science ®Google Scholar
• Lucas K. G., Pollok K. E., Emanuel D. J. POST-TRANSPLANT EBV INDUCED LYMPHOPROLIF-ERATIVE DISORDERS [Review]. Leukemia & Lymphoma 1997; 25: 1–8
   PubMed Web of Science ®Google Scholar
• Sullivan K. M., Storb R., Buckner C D., Fefer A., Fisher L., Weiden P L., Witherspoon R. P., Appelbaum F. R., Banaji M., Hansen J., et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. New England Journal of Medicine 1989; 320: 828–34
   PubMed Web of Science ®Google Scholar
• Slavin S., Strober S. Spontaneous murine B-cell leukemia. Nature 1978; 111: 624
   Web of Science ®Google Scholar
• Maloney D. G., Kaminski M. S., Burowski D., Haimovich J., Levy R. Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13: characterization and use as probes for the biology of the tumor in vivo and in vitro. Hybridoma 1986; 4: 191–209
   Web of Science ®Google Scholar
• Meeker T. C., Lowder J., Maloney D. G., Miller R. A., Thiele-Mans K., Warnke R., Levy R. A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 1985; 65: 1349–63
   PubMed Web of Science ®Google Scholar
• Lowder J. N., Meeker T. C., Campbell M., Garcia C. F., Gralow J., Miller R. A., Warnke R., Levy R. Studies on B lymphoid tumors treated with monoclonal anti-idiotype antibodies: correlation with clinical responses. Blood 1987; 69: 199–210
   PubMed Web of Science ®Google Scholar
• Levy R., Miller R. A. Therapy of lymphoma directed at idiotypes. Journal ofthe National Cancer Institute. Monographs 1990; 61–8
   Google Scholar
• Nadler L. M., Stashenko P., Hardy R., Kaplan W. D., Button L. N., Kufe D. W., Amman K. H., Schlossman S. F. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Research 1980; 40: 3147–54
   PubMed Web of Science ®Google Scholar
• Weiner G. J., Kaminski M. S. Idiotype variants emerging after anti-idiotype monoclonal antibody therapy of a murine B cell lymphoma. Journal of Immunology 1989; 142: 343–51
   PubMed Web of Science ®Google Scholar
• Jefferis R., Lund J., Pound J. Molecular definition of interaction sites on human IgG for Fc receptors (huFc gamma R). Molecular Immunology 1990; 27: 1237–40
   PubMed Web of Science ®Google Scholar
• Slavin-Chiorini D. C., Horan Hand P H., Kashmiri S. V., Calvo B., Zaremba S., Schlom J. Biologic properties of a CH2 domain-deleted recombinant immunoglobulin. International Journal of Cancer 1993; 53: 97–103
   PubMed Web of Science ®Google Scholar
• Lobuglio A. F., Wheeler R. H., Trang J., Haynes A., Rogers K., Harvey E. B., Sun L., Ghrayeb J., Khazaeli M. B. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proceedings of the National Academy of Sciences ofthe United States of America 1989; 86: 4220–4
   PubMed Web of Science ®Google Scholar
• Davis T., Levy R., White C. A., Maloney D. G., Link B. K., Velasquez C., Varns C., Gardner C., Grillo-Lopez A. J. Retreatments with RITUXAN (Rituximab, IDEC-C2b8) have significant efficacy, do not cause HAMA, and are a viable minimally toxic alternative in relapsed or refractory non-Hodgkin's lymphoma (NHL). Blood 1996; 90: 509a
   Web of Science ®Google Scholar
• Riechmann L., Clark M., Waldmann H., Winter G. Resharping human antibodies for therapy. Nature 1988; 332: 323
   PubMed Web of Science ®Google Scholar
• Queen C., Schneider W. P., Selick H. E., Payne P. W., Landolfi N. F., Duncan J. F., Avdalovic N. M., Levitt M., Junghans R. P., Waldmann T. A. A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl.Acad. Sci. USA 1989; 86: 10029–10033
   PubMed Web of Science ®Google Scholar
• Fujimori K., Covell D. G., Fletcher J. E., Weinstein J. N. A modeling analysis of monoclonal antibody percola tion through tumors: a binding-site barrier. Journal of Nuclear Medicine 1990; 31: 1191–8
   PubMed Web of Science ®Google Scholar
• Chignola R., Pasti M., Candiani C., Franceschi A., Anselmi C., Tridente G., Colombatti M. Escape mechanisms of human leukemic cells to long-term immunotoxin treatment in an in vitro experimental model. Int J Cancer 1995; 61: 535–541
   PubMed Web of Science ®Google Scholar
• Hirsch R., Gress R. E., Pluznik D. H., Eckhaus M., Blue-Stone J. A. Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells. J Immunol 1989; 142: 737–43
   PubMed Web of Science ®Google Scholar
• Vervoordeldonk S. F., Merle P. A., Van Leeuwen E. F., Von Dem Borne A. E., Slaper-Cortenbach I. C. Preclinical studies with radiolabeled monoclonal antibodies for treatment of patients with B-cell malignancies. Cancer 1994; 73: 1006–11
   PubMed Web of Science ®Google Scholar
• Meeker T., Lowder J., Cleary M. L., Stewart S., Warnke R., Sklar J., Levy R. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. NEngl J Med 1985; 312: 1658–65
   PubMed Web of Science ®Google Scholar
• Baluyut A. R., Pollok K. E., Bondada S. Molecular events in B lymphocyte activation: Consequences of signals transduced through MHC class II molecules. Cellular Immunology 1993; 147: 353–366
   PubMed Web of Science ®Google Scholar
• Barrett T. B., Shu G. L., Draves K. E., Pezzutto A., Clark E. A. Signaling through CD19, Fc receptors or transforming growth factor-beta: each inhibits the activation of resting human B cells differently. European Journal of Immunology 1990; 20: 1053–9
   PubMed Web of Science ®Google Scholar
• Beckwith M., Urba W. J., Ferris D. K., Freter C. E., Kuhns D. B., Moratz C M., Longo D. L. Anti-IgM-medi-ated growth inhibition of a human B lymphoma cell line is independent of phosphatidylinositol turnover and protein kinase C activation and involves tyrosie phosphorylation. Journal of Immunology 1991; 147: 2411–2418
   PubMed Web of Science ®Google Scholar
• Beiske K., Clark E. A., Holte H., Ledbetter J. A., Smeland E. B., Godal T. Triggering of neoplastic B cells via surface IgM and the cell surface antigens CD20 and CDw40. Responses differ from normal blood B cells and are restricted to certain morphologic subsets. International Journal of Cancer 1988; 42: 521–8
   PubMed Web of Science ®Google Scholar
• Bishop G. A., Warren W. D., Berton M. T. Signaling via major histocompatibility complex class II molecules and antigen receptors enhances the B cell response to gp39/CD40 ligand. Eur J Immunol 1995; 25: 1230–1238
   PubMed Web of Science ®Google Scholar
• Clark E. A., Shu G. Activation of human B cell proliferation through surface Bp35 (CD20) polypeptides or immunoglobulin receptors. Journal of Immunology 1987; 138: 720–5
   PubMed Web of Science ®Google Scholar
• Doody G. M., Dempsey P. W., Fearon D. T. Activation of B lymphocytes: Integrating signals from CD19, CD22 and Fc gamma Rllbl. Curr Opin Immunol 1996; 8: 378–382
   PubMed Web of Science ®Google Scholar
• Ledbetter J. A., Shu G., Gallagher M., Clark E. A. Augmentation of normal and malignant B cell proliferation by monoclonal antibody to the B cell-specific antigen BP50 (CDW40). Journal of Immunology 1987; 138: 788–94
   PubMed Web of Science ®Google Scholar
• Tedder T. F., Forsgren A., Boyd A. W., Nadler L. M., Schlossman S. F. Antibodies reactive with the Bl molecule inhibit cell cycle progression but not activation of human B lymphocytes. European Journal of Immunology 1986; 16: 881–7
   PubMed Web of Science ®Google Scholar
• Brown S. L., Miller R. A., Levy R. Antiidiotype antibody therapy of B-cell lymphoma. Semin Oncol 1989; 16: 199–210
   PubMed Web of Science ®Google Scholar
• Miller R. A., Maloney D. G., Warnke R., Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. New England Journal of Medicine 1982; 306: 517–22
   PubMed Web of Science ®Google Scholar
• Vlasveld L. T., Hekman A., Vythdreese F. A., Melief C. J.M., Sein J. J., Voordouw A. C., Dellemijn T. A.M., Rankin E. M. Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19. Cancer Immunol Immunother 1995; 40: 37–47
   PubMed Web of Science ®Google Scholar
• Press O. W., Appelbaum E., Ledbetter J. A., Martin P. J., Zariing J., Kidd P., Thomas E. D. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 1987; 69: 584–91
   PubMed Web of Science ®Google Scholar
• Scheinberg D. A., Straus D. J., Yeh S. D., Divgi C., Garin-Chesa P., Graham M., Pentlow K., Coit D., Oettgen H. F., Old L. J. A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression. Journal of Clinical Oncology 1990; 8: 792–803
   PubMed Web of Science ®Google Scholar
• Canon P C, Schwartz M. A., Co M. S., Queen C., Finn R. D., Graham M. C., Divgi C. R., Larson S. M., Scheinberg D. A. Murine and Humanized Constructs of Monoclonal Antibody M195 (Anti-Cd33) for the Therapy of Acute Myelogenous Leukemia. Cancer 1994; 73: 1049–1056
   PubMed Web of Science ®Google Scholar
• Haga Y., Sivinski C. L., Woo D., Tempero M. A. Dose-related comparison of antibody-dependent cellular cytotoxicity with chimeric and native murine monoclonal antibody 17–1A. Improved cytolysis of pancreatic cancer cells with chimeric 17–1A. International Journal of Pancre-atology 1994; IS: 43–50
   Google Scholar
• Meredith R. F., Khazaeli M. B., Grizzle W. E., Orr R. A., Plott G., Urist M. M., Liu X., Russell C D., Wheeler R. H., Schlom J., et al. Direct localization comparison of murine and chimeric B72.3 antibodies in patients with colon cancer. Human Antibodies & Hybridomas 1993; 4: 190–7
   PubMedGoogle Scholar
• Weiden P. L., Breitz H. B., Seiler C. A., Bjorn M. J., Ratliff B. A., Mallett R., Beaumier P L., Appelbaum J. W., Fritzberg A. R., Salk D. Rhenium-186–1 abeled chimeric antibody NR-LU-13: pharmacokinetics, biodistribution and immunogenicity relative to murine analog NR-LU-10. Journal of Nuclear Medicine 1993; 34: 2111–9
   PubMed Web of Science ®Google Scholar
• Dyer M. J. Chimeric antibodies for the treatment of hematologic malignancy. (72 Refs). Cancer Treatment & Research 1993; 68: 161–80
   PubMedGoogle Scholar
• Shitara K., Kuwana Y., Nakamura K., Tokutake Y., Ohta S., Miyaji H., Hasegawa M., Hanai N. A mouse/human chimeric anti-(ganglioside GD3) antibody with enhanced antitumor activities. Cancer Immunology, Immunotherapy 1993; 36: 373–80
   PubMed Web of Science ®Google Scholar
• Dyer M. J., Hale G., Marcus R., Waldman R. Remission induction in patients with lymphoid malignancies using unconjugated Campath-1 monoclonal antibodies. Leukemia and Lymphoma 1990; 2: 179–193
   PubMed Web of Science ®Google Scholar
• Dyer M. J., Hale G., Hayhoe F. G., Waldmann H. Effects Of Campath-1 Antibodies In Vivo In Patients With Lymphoid Malignancies: Influence Of Antibody Isotype. Blood 1989; 73: 1431–9
   PubMed Web of Science ®Google Scholar
• Xia M. Q., Hale G., Waldmann H. Efficient complement mediated-lysis of cells containing the Campath-1 H (CDw52) antigen. Molecular Immunology 1993; 30
   Web of Science ®Google Scholar
• Osterborg A., Dyer M. J., Bunjes D., Pangalis G. A., Bastion Y., Catovsky D., Mellstedt H. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAM-PATH-1H Treatment in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology 1997; 15: 1567–74
   PubMed Web of Science ®Google Scholar
• Osterborg A., Fassas A. S., Anagnostopoulos A., Dyer M. J., Catovsky D., Mellstedt H. Humanized CD52 monoclonal antibody Campath-1 H as first-line treatment in chronic lymphocytic leukaemia. British Journal of Haema-tology 1996; 93: 151–3
   PubMed Web of Science ®Google Scholar
• Tang S. C., Hewitt K., Berinstein N. L. Objective clinical responses in patients with recurrent low grade lymphoma treated with CAMPATH-1 H monoclonal antibody (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1995; 14: A1255
   Google Scholar
• De Nully Brown P., Hansen M. M., Nissen N. I. [Campath-1H-a monoclonal antibody for treatment of non-Hodgkin's and chronic lymphatic leukemia]. Ugeskrifi forLaeger 1997; 159: 4389–93
   PubMedGoogle Scholar
• Bowen A. L., Zomas A., Emmett E., Matutes E., Dyer M. J., Catovsky D. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-pro-lymphocytic leukaemia. British Journal of Haematology 1997; 96: 617–9
   PubMed Web of Science ®Google Scholar
• Reff M. E., Carner K., Chambers K. S., Chinn P. C., Leonard J. E., Raab R., Newman R. A., Hanna N., Anderson D. R. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435–45
   PubMed Web of Science ®Google Scholar
• Maloney D. G., Liles T. M., Czerwinski D. K., Waldichuk C., Rosenberg J., Grillo-Lopez A., Levy R. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457–66
   PubMed Web of Science ®Google Scholar
• Maloney D. G., Grillolopez A. J., White C. A., Bodkin D., Schilder R. J., Neidhart J. A., Janakiraman N., Foon K. A., Liles T. M., Dallaire B. K., Wey K., Royston I., Davis T., Levy R. Idec-C2b8 (Rituximab) Anti-Cd20 Monoclonal Antibody Therapy Patients With Relapsed Low-Grade Non-Hodgkins Lymphoma. Blood 1997; 90: 2188–2195
   PubMed Web of Science ®Google Scholar
• Maloney D. G., Grillo-Lopez A. J., Bodkin D. J., White C. A., Liles T. M., Royston I., Varns C., Rosenberg J., Levy R. Idec-C2b8 - Results Of a Phase I Multiple-Dose Trial In Patients With Relapsed Non-Hodgkins Lymphoma. Journal of Clinical Oncology 1997; 15: 3266–3274
   PubMed Web of Science ®Google Scholar
• McLaughlin P., Grillo-Lopez A. J., Czuczman M., Link B. K., Levy R., Dillman R. O., Ho A., Bennett J. M., Heyman M. R., Schilder R. J., Cabanillas R., Rogers J., Dallaire B. K. Preliminary Report on a Phase III Pivotal Trial of the Anti-CD20 Antibody IDEC-C2B8 in Patients with Relapsed Low Grade or Follicular Lymphoma. Proceedings American Society of Clinical Oncology 1996; 15: 417
   Google Scholar
• Demidem A., Lam T., Alas S., Hariharan K., Hanna N., Bonavida B. Chimeric Anti-Cd20 (Idec-C2b8) Monoclonal Antibody Sensitizes Cell Lymphoma Cell Line to Cell Killing By Cytotoxic Drugs. Cancer Biotherapy & Radiopharmaceuticals 1997; 12: 177–186
   PubMed Web of Science ®Google Scholar
• Czuczman M., Grillo-Lopez A. J., Saleh M., Gordon L., Jonas C., Varns C. Phase II clinical trial of IDEC-C2B8/CHOP combination therapy in low-grade lymphoma: preliminary results (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1995; 14: A1261
   Google Scholar
• Herpst J. M., Klein J. L., Leichner P. K., Quadri S. M., Vriesendorp H. M. Survival of patients with resistant Hodgkin's disease after polyclonal yttrium 90-labeled antiferritin treatment. Journal of Clinical Oncology 1995; 13: 2394–400
   PubMed Web of Science ®Google Scholar
• Corcoran M. C., Eary J., Bernstein I., Press O. W. Radioimmunotherapy strategies for non-Hodgkin's lymphomas. Annals of Oncology 1997; 8: 133–8
   PubMed Web of Science ®Google Scholar
• Wilder R. B., Denardo G. L., Denardo S. J. Radioimmunotherapy: recent results and future directions. Journal of Clinical Oncology 1996; 14: 1383–400
   PubMed Web of Science ®Google Scholar
• Appelbaum F. R. Radiolabeled Monoclonal Antibodies in the Treatment of Non-Hodgkin's Lymphoma. Hematology - Oncology Clinics of North America 1991; 5: 1013–1025
   PubMed Web of Science ®Google Scholar
• Knox S. J., Levy R., Miller R. A., Uhland W., Schiele J., Ruehl W., Finston R., Day L. P., Goris M. L. Determinants of the antitumor effect of radiolabeled monoclonal antibodies. Cancer Res 1990; 50: 4935–40
   PubMed Web of Science ®Google Scholar
• Mattes M. J., Griffiths G. L., Diril H., Goldenberg D. M., Ong G. L., Shih L. B. Processing of Anti-body-Radioisotope Conjugates After Binding to the Surface of Tumor Cells. Cancer 1994; 73: 787–793
   PubMed Web of Science ®Google Scholar
• Buchsbaum D. J., Wahl R. L., Glenn S. D., Normolle D. P., Kaminski M. S. Improved Delivery of Radiolabeled Anti-B1 Monoclonal Antibody to Raji Lymphoma Xenografts by Predosing with Unlabeled Anti-B1 Monoclonal Antibody. Cancer Res 1992; 52: 637–642
   PubMed Web of Science ®Google Scholar
• Press O. W., Eary J. F., Appelbaum F. R., Martin P. J., Badger C. C., Nelp W. B., Glenn S., Butchko G., Fisher D., Porter B., et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support [see comments]. New England Journal of Medicine 1993; 329: 1219–24
   PubMed Web of Science ®Google Scholar
• Press O. W., Eary J. F., Appelbaum F. R., Martin P. J., Nelp W. B., Glenn S., Fisher D. R., Porter B., Matthews D. C., Gooley T., et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995; 346: 336–40
   PubMed Web of Science ®Google Scholar
• Kaminski M. S., Fig L. M., Zasadny K. R., Koral K. F., Delrosario R. B., Francis I. R., Hanson C. A., Normolle D. P., Mudgett E., Liu C. P., Moon S., Scott P., Miller R. A., Wahl R. L. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. Journal of Clinical Oncology 1992; 10: 1696–1711
   PubMed Web of Science ®Google Scholar
• Kaminski M. S., Zasadny K. R., Francis I. R., Fenner M. C., Ross C. W., Milik A. W., Estes J., Tuck M., Regan D., Fisher S., Glenn S. D., Wahl R. L. Iodine - 131-anti-B1 radioimmunotherapy for B-cell lymphoma. Journal of Clinical Oncology 1996; 17: 1974–1981
   Google Scholar
• Lewis J. P., Denardo G. L., Denardo S. J. Radioimmunotherapy of lymphoma: a UC Davis experience. Hybridoma 1995; 14: 115–20
   PubMed Web of Science ®Google Scholar
• Goldenberg D. M., Horowitz J. A., Sharkey R. M., Hall T. C., Murthy S., Goldenberg H., Lee R. E., Stein R., Siegel J. A., Izon D. O., et al. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody [see comments]. Journal of Clinical Oncology 1991; 9: 548–64
   PubMed Web of Science ®Google Scholar
• Knox S. J., Goris M. L., Trisler K., Negrin R., Davis T., Liles T.-M., Grillo-Lopez A., Chinn P., Varns C., Shou-Cheng N., Fowler S., Nimisha D., Becker M., Marquez C., Levy R. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clinical Cancer Research 1996; 2: 457–470
   PubMed Web of Science ®Google Scholar
• White C. A., Halpern S. E., Parker B. A., Miller R. A., Hupf H. B., Shawler D. L., Collins H. A., Royston I. Radioimmunotherapy of relapsed B-cell lymphoma with Yttrium anti-idiotype monoclonal antibodies. Blood 1996; 87: 3640–3649
   PubMed Web of Science ®Google Scholar
• Frankel A. E., Fitzgerald D., Siegall C., Press O. W. Advances in immunotoxin biology and therapy: A summary of the Fourth International Symposium on Immunotoxins. Cancer Res 1996; 56: 926–932
   PubMed Web of Science ®Google Scholar
• Ghetie V., Vitetta E. Immunotoxins in the therapy of cancer: From bench to clinic. Pharmacol Ther 1994; 63: 209–234
   PubMed Web of Science ®Google Scholar
• Grossbard M. L., Nadler L. M. Immunotoxin Therapy of Lymphoid Neoplasms. Semin Hematol 1994; 31: 88–97
   PubMed Web of Science ®Google Scholar
• Vitetta E. S., Stone M., Amlot P., Fay J., May R., Till M., Newman J., Clark P., Collins R., Cunningham D., Ghetie V., Uhr J. W., Thorpe P. E. Phase-I Immunotoxin Trial in Patients with B-Cell Lymphoma. Cancer Research 1991; 51: 4052–4058
   PubMed Web of Science ®Google Scholar
• Amlot P. J., Stone M. J., Cunningham S. D., Fay J., Collins N. R., May R., McCarthy M., Richardson J., Ghetie V., Ramilo O., Thorpe P. E., Uhr J. W., Vitetta E. S. A phase 1 study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 1993; 82: 2624–2633
   PubMed Web of Science ®Google Scholar
• Sausville E. A., Headlee D., Stetler-Stevenson M., Jaffe E. S., Solomon D., Figg W. D., Herdt J., Kopp W. C., Rager H., Steinberg S. M., et al. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study. Blood. 1995; 85: 3457–65
   PubMed Web of Science ®Google Scholar
• Stone M. J., Sausville E. A., Fay J. W., Headlee D., Collins R. H., Figg W. D., Stetler-Stevenson M., Jain V., Jaffe E. S., Solomon D., Lush R. M., Senderowicz A., Ghetie V., Schlindler J., Uhr J. W., Vitetta E. S. A phase I study of bolus versus continuous infusion of the anti-CD 19 immunotoxin, Ig-HD37-dgA in patients with B-cell lymphoma. Blood 1996; 88: 118–1197
   Web of Science ®Google Scholar
• Grossbard M. L., Freedman A. S., Ritz J., Coral R., Goldmacher V. S., Eliseo L., Spector N., Dear K., Lambert J. M., Blat-Tler W. A., Taylor J. A., Nadler L. M. Serotherapy of B-Cell Neoplasms with Anti-B4-Blocked Ricin - A Phase-I Trial of Daily Bolus Infusion. Blood 1992; 79: 576–585
   PubMed Web of Science ®Google Scholar
• Grossbard M. L., Lambert J. M., Goldmacher V. S., Spector N. L., Kinsella J., Eliseo L., Coral R., Taylor J. A., Blattler W. A., Epstein C. L., Nadler L. M. Anti-B4-Blocked Ricin - A Phase-I Trial of 7-Day Continuous Infusion in Patients with B-Cell Neoplasms. J Clin Oncol 1993; 11: 726–737
   PubMed Web of Science ®Google Scholar
• Grossbard M. L., Gribben J. G., Freedman A. S., Lambert J. M., Kinsella J., Rabinowe S. N., Eliseo L., Taylor J. A., Blattler W. A., Epstein C. L., Nadler L. M. Adjuvant Immunotoxin Therapy with Anti-B4-Blocked Ricin After Autologous Bone Marrow Transplantation for Patients with B-Cell Non-Hodgkin's Lymphoma. Blood 1993; 81: 2263–2271
   PubMed Web of Science ®Google Scholar
• Grossbard M. L., O'Day S., Gribben J. G., Kolesar C., Freedman A. S., Rabinowe S. N., Neuberg D., Esseltine D. L., Epstein C. L., Nadler L. M. A Phase II study of anti-B4-blocked ricin (anti-B4-bR) therapy following autologous bone marrow transplantation (ABMT) for B-cell non-Hodgkin's lymphoma (B-NHL) (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1994; 13: A951
   Google Scholar
• Vuist W. M.J., Levy R., Maloney D. G. lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein. Blood 1994; 83: 899–906
   PubMed Web of Science ®Google Scholar
• Vitetta E. S., Tucker T. R, Racila E., Huang Y. W., Marches R., Lane N., Scheuermann R. H., Street N. E., Watanabe T., Uhr J. W. Tumor dormancy and cell signaling. V. Regrowth of the BCL1 tumor after dormancy is established. Blood 1997; 89: 4425–36
   PubMed Web of Science ®Google Scholar